Fibrinogen Activity Test · Blood

If your standard bloodwork comes back clean but you still want to know how much silent inflammation and clotting risk your body is carrying, fibrinogen activity is one of the most underused numbers in preventive medicine. It predicts heart attack, stroke, and death from all causes with a strength that rivals cholesterol, yet it does not appear on a routine blood panel.

Fibrinogen activity measures how well the fibrinogen protein in your blood can be converted into fibrin, the mesh that holds a blood clot together. A single reading captures two things at once: your body's capacity to stop bleeding and the level of chronic, low grade inflammation circulating in your bloodstream.

What Fibrinogen Is and Why It Matters

Fibrinogen is a large protein produced by liver cells and released into the bloodstream. When you get a cut or an artery wall is damaged, an enzyme called thrombin clips fibrinogen into smaller pieces called fibrin monomers. These monomers link together into a web of fibers that, along with platelets, forms the physical structure of a blood clot. Without enough functional fibrinogen, clots are fragile and bleeding becomes difficult to stop.

Fibrinogen is also what scientists call an acute phase protein, meaning the liver produces more of it whenever the body senses infection, injury, or chronic stress on blood vessel walls. Levels can rise two to threefold during an acute inflammatory episode. This means a high fibrinogen reading does not just tell you about clotting. It tells you the body's inflammatory alarm system is active.

Heart Disease Risk

The strongest evidence linking fibrinogen to hard outcomes comes from the Fibrinogen Studies Collaboration, a pooled analysis of 31 prospective studies covering 154,211 adults without prior cardiovascular disease and 1.38 million person years of follow up. For every 1 g/L increase in usual fibrinogen, the risk of coronary heart disease was roughly 2.4 times higher, the risk of stroke about twice as high, and the risk of dying from other vascular causes nearly 2.8 times higher. After adjusting for blood pressure, cholesterol, smoking, and other standard risk factors, the risk of coronary heart disease and stroke remained about 80% higher per 1 g/L increment.

In a subset of 7,011 participants where both fibrinogen and CRP (high sensitivity C reactive protein, another inflammation marker) were measured, adjusting for CRP did not weaken the fibrinogen association with coronary heart disease. This suggests fibrinogen captures cardiovascular risk information that even CRP does not fully account for.

Among people who already have heart disease, the picture is even sharper. A meta analysis of 13 studies totaling 20,395 coronary artery disease patients found that those in the highest fibrinogen category had about 2.2 times the risk of dying from cardiovascular causes and about 1.9 times the risk of dying from any cause compared with those in the lowest category.

Fibrinogen and Diabetes: A Dangerous Combination

In a study of 6,140 patients with coronary artery disease who underwent stent placement, those in the highest fibrinogen tertile had about 86% higher risk of all cause death and 82% higher risk of cardiac death over a median 5.1 years compared to the lowest tertile, after adjusting for conventional risk factors. When diabetes was layered on top, the risk compounded: patients with diabetes and high fibrinogen had about three times the mortality risk of those with normal blood sugar and low fibrinogen.

This interaction between fibrinogen and blood sugar control means that if you have prediabetes or type 2 diabetes, fibrinogen is not just a nice to know number. It is a meaningful piece of the risk puzzle that standard glucose and cholesterol tests do not capture.

Sudden Cardiac Death

In the Kuopio Ischemic Heart Disease study, 1,773 Finnish men without heart failure were followed for 22 years, during which 131 experienced sudden cardiac death. For each standard deviation increase in baseline fibrinogen, the fully adjusted risk of sudden cardiac death was about 32% higher. After correcting for the natural variability in fibrinogen over time (which means the true long term average was likely higher than any single reading), the risk roughly doubled. A meta analysis combining three cohorts confirmed this pattern: each standard deviation increase in long term average fibrinogen was associated with about twice the risk of sudden cardiac death.

All Cause Mortality

In NHANES data covering over 18,000 U.S. adults followed for a median of about 6 years, those in the highest fibrinogen quartile had roughly double the risk of dying from any cause compared with the lowest quartile after full adjustment. The Fibrinogen Studies Collaboration found a similar pattern: for each 1 g/L increase, non vascular death (predominantly cancer and other causes) was about twice as likely.

A separate NHANES III analysis of 4,730 adults followed for nearly 20 years showed that people whose fibrinogen and lipoprotein(a) (a genetically determined cholesterol particle) were both in the top 10th percentile had about 2.4 times the risk of dying from cancer and about 2.1 times the risk of dying from cardiovascular disease, compared to those with both markers below the 50th percentile.

Is Fibrinogen a Cause or Just a Marker?

This is a fair question. A large genetic study of over 90,000 Europeans identified 24 independent genetic signals that raise fibrinogen levels, accounting for about 3.7% of fibrinogen variation in the population. When researchers tested whether people who carry more of these fibrinogen raising gene variants also have more heart disease, they did not find a clear link. Combined genetic scores for higher fibrinogen were not associated with coronary artery disease, stroke, or venous blood clots.

This suggests that fibrinogen is a powerful marker of risk, reflecting the broader inflammatory and metabolic environment that drives cardiovascular disease, rather than a direct cause in the way that LDL cholesterol particles are. That distinction matters for treatment: lowering fibrinogen may not directly prevent heart attacks the way lowering LDL does. But it does not make the measurement less useful. A high fibrinogen reading is a reliable signal that something in your body's inflammatory and clotting balance needs attention, even if the fix is not fibrinogen specific.

Reference Ranges

Fibrinogen activity is measured using the Clauss assay, a lab technique that tests how quickly your plasma forms a clot when exposed to a high concentration of thrombin. Results are reported in mg/dL or g/L. Fibrinogen rises with age and tends to be slightly higher in women than in men, especially with hormone therapy. The ranges below are drawn from population studies using the Clauss method in healthy adults. Your own lab may use slightly different cutpoints depending on the analyzer.

Compare your results within the same lab over time for the most meaningful trend. A single reading in the mildly elevated range during an acute illness may mean nothing; a consistently elevated reading across multiple draws, weeks apart, is a genuine signal.

When Results Can Be Misleading

Fibrinogen has a within person biological variation of about 10 to 12% in healthy, stable individuals. That means your number can fluctuate meaningfully from one blood draw to the next even when nothing has changed clinically. Averaging at least two measurements, taken weeks apart under standardized conditions (morning, fasting, no recent illness), gives a much more reliable picture of your true baseline.

• Recent infection or surgery: Any acute illness, injury, or surgical procedure can spike fibrinogen by 50% or more for days to weeks. Wait at least two to three weeks after recovering from a significant illness before drawing labs for baseline purposes.
• Seasonal variation: Fibrinogen shows measurable seasonal shifts, accounting for roughly 11% of total variance in some studies. A winter reading may be higher than a summer one from the same person.
• Obesity and metabolic inflammation: Higher body mass index is strongly associated with higher fibrinogen through chronic low grade inflammation. Weight loss after bariatric surgery reduces fibrinogen by about 17% on average. This is a real biological change, not a testing artifact, but it means an overweight person's fibrinogen may partly reflect body composition rather than an independent vascular risk.
• Rosuvastatin: This statin can cause a small increase in fibrinogen (about 0.17 g/L) after four weeks of use. The clinical significance is minimal, but it could shift a borderline reading slightly upward.